Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Nicotinamide riboside shows promise for myocardial infarction

Sep. 10, 2019

Acesion presents data on the selective negative allosteric SK channel modulator AP-30663

Sep. 6, 2019

Bristol-Myers Squibb describes preclinical profile of apelin receptor agonist BMS-986224

Sep. 6, 2019

Applied Therapeutics begins phase III study of AT-1001 for diabetic cardiomyopathy

Sep. 5, 2019

Fulacimstat does not improve standard of care treatment in CHIARA MIA 2 study

Sep. 4, 2019

BMS-986235 shows efficacy in preclinical models of heart failure

Sep. 4, 2019

eXIthera Pharmaceuticals divulges coagulation factor XIa and kallikrein inhibitors

Sep. 3, 2019

UCn2 gene transfer improves diabetes-related left-ventricular dysfunction in mice

Sep. 3, 2019

First preclinical data presented on miR-132 inhibitor CDR132L in heart failure model

Sep. 3, 2019

Phase II data reported for P2Y12 inhibitor selatogrel in CAD patients

Sep. 2, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....